表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、审议通过了公司 2023 年半年度《募集资金存放与实际使用 情况的专项报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 证券代码：600329 证券简称：达仁堂 编号：临 2023-032 号 津药达仁堂集团股份有限公司 2023 年第四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2023 年 8 月 4 日发出会议通知，并于 2023 年 8 月 14 日 以现场结合通讯方式召开了 2023 年第四次监事会会议，会议应到监 事 3 名，实到监事 3 名。本次会议召开符合公司章程的有关规定，经 与会监事认真审议，形成如下决议： 一、审核公司 2023 年半年度报告无误，并发表审核意见如下： 1．公司 2023 年半年度报告的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定； 2．公司 2023 年半年度报告的内容和格式符合中国证监会和证券 交易所的各项规定，所包含的信息从各个方面真实地反映出公司当期 的经营 ...

津药达仁堂集团股份有限公司将于 2023 年 8 月 14 日以现场结合 通讯方式召开了 2023 年第五次董事会会议。会议将审议"聘任公司 2023 年度审计机构的议案"。 根据中国证监会《关于在上市公司建立独立董事制度的指导意 见》、《上市公司治理准则》，上海证券交易所《股票上市规则》和新 加坡交易所有关规则、本公司《公司章程》与《独立董事制度》等相 关规定，作为公司独立董事，我们在事前对本次事项进行认真研究， 基于独立判断的立场，发表如下意见： 津药达仁堂集团股份有限公司 关于公司 2023 年第五次董事会相关事项的 独立董事事前认可意见 中审华会计师事务所（特殊普通合伙）具备证券、期货相关业务 执业资格，具备为上市公司提供审计服务的经验与能力，能够满足公 司 2023 年度境内财务报告审计及内部控制审计工作的要求。胡官陈 有限责任合伙会计师事务所（FKT）是由中审华会计师事务所（特殊 普通合伙）推荐的境外审计机构，两家审计机构具备良好地合作关系， 有利于确保境内外审计工作高效完成。胡官陈有限责任合伙会计师事 务所（FKT）能够满足公司 2023 年度境外财务报告的审计工作。我 们同意将聘任中审华会计师 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-031 号 津药达仁堂集团股份有限公司 2023 年第五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司于 2023 年 8 月 4 日发出会议通知， 并于 2023 年 8 月 14 日以现场结合通讯方式召开了 2023 年第五次董 事会会议。本次会议应参加董事 9 人，实参加董事 9 人。会议召开符 合《公司法》、《证券法》和《公司章程》有关召开董事会会议的规定。 会议形成如下决议： 一、审议通过了公司 2023 年中国准则半年度报告全文、摘要以 及国际准则的中期报告。 据本公司董事会全体成员及管理层所知，没有任何其他信息将致 使该报告不确实或具有误导性。 表决结果：同意 9 票，反对 0 票，弃权 0 票 二、审议通过了公司 2023 年半年度《募集资金存放与实际使用 情况的专项报告》。（详见临时公告 2023-033 号） 四、审议通过了公司继续使用不超过 5 亿元人民币自有资金进行 现金管理的议案。 1 公司于 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-034 号 津药达仁堂集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2015年8月26日，公司2015年第八次董事会及2015年第五次监事会审议通过 了《关于使用部分闲置募集资金暂时补充公司流动资金的议案》，公司使用部分 闲置募集资金2.5亿元补充公司流动资金，使用期限自批准之日起不超过12个月。 1 2016年8月23日，公司已将上述用于暂时补充流动资金的募集资金全部归还至募 集资金专户。 2016年8月24日，公司2016年第七次董事会及2016年第五次监事会审议通过 了《关于继续使用部分闲置募集资金暂时补充公司流动资金的议案》，公司使用 部分闲置募集资金2.5亿元补充公司流动资金，使用期限自批准之日起不超过12 个月。2017年8月22日，公司已将上述用于暂时补充流动资金的募集资金全部归 还至募集资金专户。 2017年8月23日，公司2017年第七次董事会及2017年第四次监事会审议通过 了《 ...

津药达仁堂集团股份有限公司（以下简称"公司"）2022 年第 四次董事会审议通过了《关于继续使用部分闲置募集资金暂时补充公 司流动资金的议案》，同意公司使用部分闲置募集资金 4 亿元补充公 司流动资金，使用期限自董事会批准之日起不超过 12 个月，到期将 归还至公司募集资金专户。相关具体内容详见 2022 年 8 月 15 日在《中 国证券报》、《上海证券报》及上海证券交易所网站（www.sse.com.cn） 上刊登的《关于使用部分闲置募集资金暂时补充流动资金的公告》 （临时公告 2022-026 号）。 截至 2023 年 8 月 10 日，公司已将上述用于暂时补充流动资金的 募集资金全部归还至募集资金专户，并已将上述募集资金的归还情况 通知了保荐机构及保荐代表人。 特此公告。 津药达仁堂集团股份有限公司董事会 2023 年 8 月 11 日 证券代码：600329 证券简称：达仁堂 编号：临 2023-030 号 津药达仁堂集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金 到期归还的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-022 号 津药达仁堂集团股份有限公司 关于召开业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 津药达仁堂集团股份有限公司（以下简称"公司"）已分别于 2023 年 4 月 1 日、2023 年 4 月 29 日发布了 2022 年年度报告与 2023 年第一季度报告（详见上海证券交易所网站 www.sse.com.cn）。为便 于广大投资者更深入全面地了解公司经营业绩等情况，公司定于2023 年 5 月 30 日（星期二）下午 15:00—16:00 举行"业绩说明会"（以下 简称"说明会"）。 二、说明会召开时间、地点 召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 召开地点：东方财富路演 1 会议召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 会议召开地点：东方财富路演 （https://roadshow.eastmoney.com/luyan/4 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,154,405,776.85, representing a year-on-year increase of 14.03%[4] - Net profit attributable to shareholders was RMB 400,788,396.53, showing a significant increase of 100.79% compared to the same period last year[4] - Basic and diluted earnings per share both stood at RMB 0.52, marking a 100% increase year-on-year[4] - Total operating revenue for Q1 2023 reached ¥2,154,405,776.85, an increase of 14.05% compared to ¥1,889,294,355.26 in Q1 2022[16] - Net profit for Q1 2023 was ¥397,782,701.63, compared to ¥202,246,413.81 in Q1 2022, representing a growth of 96.59%[18] - Earnings per share for Q1 2023 were ¥0.52, doubling from ¥0.26 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥397,884,789.40, compared to ¥201,906,275.33 in Q1 2022, reflecting an increase of 97.00%[18] Cash Flow - The net cash flow from operating activities reached RMB 186,966,594.00, reflecting a year-on-year growth of 137.21%[4] - Cash inflow from operating activities for Q1 2023 was approximately ¥2.21 billion, an increase of 24% compared to ¥1.78 billion in Q1 2022[20] - Net cash flow from operating activities reached ¥186.97 million in Q1 2023, up from ¥78.82 million in Q1 2022, representing a growth of 137%[20] - Total cash inflow from investment activities was ¥116.36 million in Q1 2023, a decrease of 73% from ¥435.31 million in Q1 2022[21] - Net cash flow from financing activities was ¥323.50 million in Q1 2023, compared to a net outflow of ¥17.52 million in Q1 2022[21] - The net increase in cash and cash equivalents for Q1 2023 was approximately ¥582.34 million, compared to an increase of ¥411.10 million in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,866,527,859.66, up 6.99% from the end of the previous year[5] - The total liabilities have increased to RMB 3,560,725,598.61 from RMB 3,333,434,867.96, suggesting a rise in financial obligations[14] - The company's total liabilities increased to ¥3,933,820,819.32 in Q1 2023 from ¥3,605,028,900.58 in Q1 2022, marking a rise of 9.09%[17] - The total equity attributable to shareholders reached ¥6,905,220,131.40 in Q1 2023, up from ¥6,521,460,534.99 in Q1 2022, an increase of 5.88%[17] Expenses - Sales expenses rose by 39% primarily due to the increase in sales revenue[9] - Financial expenses increased by 64%, mainly attributed to higher interest costs[9] - Research and development expenses for Q1 2023 were ¥24,195,352.76, compared to ¥19,332,928.57 in Q1 2022, indicating a rise of 25.31%[17] - Cash paid to employees in Q1 2023 was ¥243.44 million, an increase of 22% from ¥199.52 million in Q1 2022[20] - Cash paid for taxes in Q1 2023 was ¥229.69 million, significantly higher than ¥98.40 million in Q1 2022, indicating a growth of 133%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,433, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, accounting for 42.811% of the total[10] Other Income - The company reported a 655% increase in other income, mainly from government subsidies received[9] - The company reported a financial income of ¥12,287,594.48 in Q1 2023, down from ¥13,078,314.45 in Q1 2022[17] Current Assets - As of March 31, 2023, the company's total current assets amount to RMB 7,903,764,059.62, an increase from RMB 7,245,444,756.23 in the previous year[13] - The company's cash and cash equivalents stand at RMB 3,455,307,279.55, compared to RMB 2,882,523,954.61 as of December 31, 2022, reflecting a significant increase[13] - Accounts receivable have risen to RMB 2,440,287,659.57 from RMB 2,146,213,416.31 year-over-year, indicating a growth in sales or credit terms[13] Financial Management - The company reported a decrease in accounts payable, which fell to RMB 686,731,735.62 from RMB 724,326,434.25, indicating improved cash flow management[14] - The company has a significant increase in short-term borrowings, which rose to RMB 351,276,795.73 from RMB 101,638,515.28[14] Intangible Assets - The company has maintained a stable level of intangible assets, which increased to RMB 332,127,671.68 from RMB 281,127,790.71[14] Product Development - The company has not disclosed any significant new product developments or market expansion strategies in the current report[12]

Financial Performance - The company achieved a net profit of ¥861,793,906.84 in 2022, representing a 12.05% increase compared to ¥769,144,377.12 in 2021[21]. - Total operating revenue for 2022 was ¥8,249,249,565.18, marking a 19.42% increase from ¥6,907,544,256.00 in 2021[21]. - The basic earnings per share rose to ¥1.12 in 2022, a 12.00% increase from ¥1.00 in 2021[23]. - The weighted average return on equity improved to 13.15% in 2022, up from 12.64% in 2021[23]. - The company reported a net profit of ¥769,227,070.99 after deducting non-recurring gains and losses, a 3.94% increase from ¥740,056,524.95 in 2021[21]. - The net profit attributable to shareholders for the fourth quarter was CNY 132,833,170.58, with a total annual net profit of CNY 1,061,793,007.84, reflecting a decrease compared to the previous year[26]. - The company achieved a total revenue of CNY 8,249,249,565.18 in 2022, representing a year-on-year increase of 19.42% compared to CNY 6,907,544,256.00 in the previous year[66]. - The net profit attributable to the parent company for 2022 was CNY 86,179,390.00, with total assets amounting to CNY 1,015,698,200.00 and net assets of CNY 655,195,310.00[64]. Cash Flow and Investments - Cash flow from operating activities decreased by 20.55% to ¥677,245,078.23 in 2022, down from ¥852,401,231.63 in 2021[21]. - The net cash flow from operating activities in the fourth quarter was CNY 550,771,466.60, significantly higher than the previous quarters[26]. - The company reported a net cash flow from investing activities of -12.28 million RMB, a significant improvement of 96.06% compared to the previous period[84]. - The company increased its long-term equity investments to CNY 760.19 million by the end of 2022, up from CNY 729.66 million at the beginning of the year[121]. - The company invested CNY 45 million in acquiring Tianjin Darentang Jingzhong Traditional Chinese Medicine, achieving 100% ownership[122]. Research and Development - In 2022, the company invested CNY 151 million in R&D, enhancing the quality standards of major products and improving drug safety and treatment experience[42]. - The company’s R&D investment accounted for 1.83% of its operating revenue, with a capitalized proportion of 4.17%[114]. - The R&D investment for the Qingfei Xiaoyan Wan major product's secondary development was CNY 107.15 million, reflecting a year-on-year increase of 108.4%[115]. - The company is actively developing two generic drugs for consistency evaluation, aiming to improve market competitiveness[107]. - The company has a total of 402 patents, including 256 invention patents, supporting its innovation and product development capabilities[62]. Market Strategy and Expansion - The company implemented a "1+5" strategic layout focusing on brand leadership and five related industries, including traditional Chinese medicine and health products[34]. - The company aims to enhance the competitiveness of the "Darentang" brand and has initiated trademark registrations and subsidiary name changes to support this strategy[34]. - The company plans to explore a combined medical and health model that incorporates traditional Chinese medicine, enhancing its service offerings[34]. - The company is focusing on the integration of traditional Chinese medicine resources and the establishment of a national chain of "Darentang" pharmacies[34]. - The company plans to expand its market presence and invest in new product development to sustain growth in the coming years[71]. Operational Efficiency - The company has established a marketing network covering the medical market, retail market, third terminal, and online channels, achieving steady progress in operational targets[44]. - The company has integrated its sales platforms, including the establishment of the commercial sales division in 2022 to operate generic drug products[38]. - The company streamlined its management structure, reducing the number of departments from 14 to 12 to better meet strategic development needs[40]. - The company is focused on optimizing smart manufacturing processes to reduce costs and improve quality, implementing lean management principles and enhancing production efficiency[140]. - The company has established a centralized procurement management system for medicinal materials, focusing on cost reduction, quality assurance, and supply stability[48]. Corporate Governance and Management - The company operates under a robust governance structure, having listings in both Singapore and Shanghai, which enhances its capital operation and financing capabilities[63]. - The company has a board of directors consisting of 8 members, with 4 independent directors[158]. - The company’s board of directors is responsible for determining the remuneration of directors and supervisors, authorized by the shareholders' meeting[167]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[175]. - The company has a clear cash dividend policy that aligns with regulatory requirements and shareholder interests[184]. Social Responsibility and Compliance - The company is committed to social responsibility and compliance, focusing on employee welfare, environmental protection, and ESG initiatives as part of its operational strategy[144]. - The company invested CNY 10.81 million in environmental protection during the reporting period[196]. - The company has strengthened its internal control system, adding 6 new regulations in 2022[192]. - The company is required to ensure compliance with new regulations regarding traditional Chinese medicine by July 2023, which mandates the submission of safety information for re-registration[148]. - The company is committed to fostering a high-performance culture by optimizing its human resource management system and implementing performance evaluation mechanisms[40]. Risks and Challenges - The company faces risks related to policy changes in the pharmaceutical industry, including the impact of centralized procurement and pricing reforms, which may introduce market uncertainties[145]. - The company is also exposed to cost pressures from rising raw material prices and labor costs, which could affect profitability and operational stability[145]. - The medical and OTC market profitability may decline due to increased buyer power represented by medical insurance payments and intensified competition within the industry[146]. - The company faces potential risks in new drug development, including failures, delays in market entry, and slow growth post-launch due to strict regulatory approvals and market conditions[147]. - The regulatory environment for drug quality has intensified since the implementation of the Drug Administration Law in December 2019, increasing the responsibility of drug marketing authorization holders[148].

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,788,247,682.39, representing a year-on-year increase of 4.47%[4] - The net profit attributable to shareholders for the same period was ¥260,175,685.17, reflecting a significant increase of 30.77% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥184,375,376.29, which showed a decrease of 3.73% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.34, up by 30.77% from the same period last year[5] - The total profit for Q3 2022 was approximately ¥847.92 million, an increase from ¥763.91 million in Q3 2021, representing a growth of about 11.1%[21] - The net profit for Q3 2022 reached approximately ¥746.21 million, compared to ¥677.00 million in Q3 2021, indicating a year-over-year increase of around 10.2%[21] - The net profit attributable to shareholders of the parent company was approximately ¥728.96 million, up from ¥661.51 million in the same quarter last year, reflecting a growth of about 10.1%[22] - The basic earnings per share for Q3 2022 was ¥0.95, compared to ¥0.86 in Q3 2021, marking an increase of approximately 10.5%[22] Assets and Liabilities - The total assets at the end of the reporting period reached ¥9,749,983,806.96, an increase of 7.53% compared to the end of the previous year[5] - The total current assets amounted to 6,915,032,966.25 yuan, an increase from 6,424,993,578.77 yuan at the end of 2021[16] - Non-current assets totaled ¥2,834,950,840.71, an increase from ¥2,642,091,427.30 in the previous year[18] - Current liabilities increased to ¥2,680,520,189.59 from ¥2,433,902,114.44, indicating a rise of 10.14%[18] - The company holds 698,495,037.33 yuan in long-term equity investments as of September 30, 2022[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥126,473,611.63, which decreased by 81.32% compared to the previous year[5] - The net cash flow from operating activities for Q3 2022 was approximately ¥126.47 million, a significant decrease from ¥677.11 million in Q3 2021[25] - Cash inflow from investment activities in Q3 2022 totaled approximately ¥653.66 million, compared to ¥189.56 million in Q3 2021, showing a substantial increase[25] - The net cash flow from investment activities for Q3 2022 was approximately ¥155.48 million, a recovery from a net outflow of ¥273.60 million in Q3 2021[25] - The company reported a total operating cash outflow of approximately ¥5.36 billion in Q3 2022, compared to ¥4.84 billion in Q3 2021, reflecting an increase of about 10.5%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,884[12] - Tianjin Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 331,120,528 shares, accounting for 42.811% of the total shares[12] - The number of shares held by the top ten shareholders includes significant foreign and domestic entities, indicating a diverse shareholder base[12] - The company has not disclosed any related party relationships among the top ten shareholders[13] Strategic Initiatives - The company has seen a 132.07% increase in capitalized research and development expenses, indicating a focus on innovation and new product development[10] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[10] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[20] Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥5,563,011,492.12, an increase of 3.94% compared to ¥5,352,222,520.14 in the same period of 2021[19] - Total operating costs for the third quarter amounted to ¥4,908,870,636.98, up from ¥4,743,067,407.38 year-over-year[20] - Operating profit for the third quarter was ¥850,221,307.98, compared to ¥756,079,156.11 in the previous year, reflecting a growth of 12.43%[20] - Research and development expenses for the first three quarters were ¥92,259,923.53, slightly down from ¥94,465,763.49 in the previous year[20] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 54.69%, primarily due to an increase in receivables from sales[10] - Accounts receivable increased to 2,377,623,755.60 yuan from 1,536,992,972.81 yuan year-over-year[16] - Inventory decreased to 1,343,866,721.60 yuan from 1,525,088,939.42 yuan year-over-year[16]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,774,763,809.73, representing a 3.69% increase compared to CNY 3,640,421,324.94 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2022 was CNY 468,785,051.09, a slight increase of 1.35% from CNY 462,548,368.85 in the previous year[16]. - The basic earnings per share for the first half of 2022 was CNY 0.61, reflecting a 1.67% increase from CNY 0.60 in the same period last year[17]. - The diluted earnings per share also stood at CNY 0.61, which is a 1.67% increase compared to CNY 0.60 in the previous year[18]. - The company reported a 4.33% increase in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY 464,246,739.81 compared to CNY 444,974,234.80 last year[16]. - The company reported a total profit for the first half of 2022 of CNY 549.82 million, compared to CNY 539.57 million in the same period of 2021, reflecting a growth of 1.5%[125]. - The total comprehensive income for the first half of 2022 was CNY 476.93 million, slightly up from CNY 471.37 million year-on-year[126]. Cash Flow and Financial Position - The net cash flow from operating activities decreased significantly by 75.92%, amounting to CNY 89,054,915.47 compared to CNY 369,883,945.76 in the same period last year[16]. - The company reported a significant increase of 124.56% in accounts receivable, reaching approximately CNY 2.17 billion, compared to CNY 1.54 billion last year[59]. - Cash and cash equivalents rose to CNY 2,596,936,387.08 from CNY 2,283,181,481.69, marking an increase of approximately 13.75%[117]. - The company reported a cash outflow from financing activities of CNY 385,237,457.71, compared to CNY 224,065,526.13 in the previous year, leading to a net cash flow from financing activities of CNY -363,706,187.30[134]. - The total assets at the end of the reporting period were CNY 9,290,068,670.30, which is a 2.46% increase from CNY 9,067,085,006.07 at the end of the previous year[16]. - Total liabilities rose to CNY 2,694,574,521.57 from CNY 2,553,255,875.58, reflecting an increase of around 5.55%[119]. Research and Development - The company possesses 402 patents, including 253 invention patents, reflecting strong research and development capabilities[40]. - The company is enhancing its research and development efforts, with key projects including the quality standard improvement of Su Xiao Jiu Xin Wan and the study of Qing Yan Di Wan's effects on coronavirus[53]. - Research and development expenses decreased by 16.66% to approximately CNY 55 million from CNY 66 million, indicating a more balanced expenditure[56]. Market and Industry Insights - The company operates in the green traditional Chinese medicine sector, covering the entire industry chain from cultivation to retail[22]. - The market share of the flagship product, "Su Xiao Jiu Xin Wan," increased from 2.43% in 2016 to 3.21% in 2021 in public health institutions[25]. - The overall revenue of China's pharmaceutical manufacturing industry in the first half of 2022 was RMB 1,400.78 billion, a decrease of 0.6% year-on-year[31]. - The industry’s total profit in the same period was RMB 220.95 billion, reflecting a decline of 27.6% compared to the previous year[31]. Strategic Initiatives - The company launched 28 new products in the first half of 2022, focusing on integrating resources and enhancing brand strength[45]. - The company is exploring the integration of online and offline channels in the healthcare sector, leveraging digital management systems for improved efficiency[36]. - The company is actively developing the Daren Tang chain pharmacy and exploring new operational models for Daren Tang hospitals[44]. Environmental and Regulatory Compliance - The company is classified as a key pollutant discharge unit in Tianjin, with three subsidiaries recognized for their environmental impact[81]. - Pollution control facilities at the company's subsidiaries are operating normally, including VOCs and wastewater treatment systems[82]. - The company has established environmental self-monitoring plans to comply with pollution discharge requirements[85]. Related Party Transactions - The controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., committed to strictly executing related party transactions according to the contract, ensuring no interference from its controlling position[88]. - The company reported a total related party transaction amount of 245,596,000.00 RMB, accounting for 10.17% of similar transactions[97]. Challenges and Risks - The company faces risks from policy changes in the pharmaceutical industry, including the implementation of the "three medical" management system and the ongoing reforms in medical insurance payment methods[69]. - Rising raw material costs in the traditional Chinese medicine sector pose a significant risk to the company's cost management and profitability[70]. - The company anticipates challenges in maintaining profit margins due to increased buyer power in the medical insurance sector and intensified competition in retail channels[70]. Corporate Governance - The company completed the renaming process, changing its name to Tianjin Daren Tang Group Co., Ltd. on May 18, 2022, marking the start of a new development phase[42]. - Zhang Yu was appointed as the Chief Manufacturing Officer (CPO) on April 28, 2022[77]. - The company does not plan to distribute profits or increase capital reserves for the half-year period[78].